Setup

Cardinal Health reported Q3 FY2026 (calendar Q1 2026) on April 30. $53B distributor, fourth consecutive guidance raise into the print, 13 buy ratings on the way in. Stock has since corrected -14.9% over the following month. The filing carried three bear signals and two bull signals; cross-checking against Lantheus (LNTH) Q1 2026 inverted what initially read as the third bear into a bull sell-side has not priced.

What the filing says

GMPD profit collapsed to $25M Q3 (-36% YoY). Sequence: $46M Q1 → $37M Q2 → $25M Q3. Filing language: "$200M cumulative IEEPA tariff charges through March 31, 2026," and explicitly: CAH tariffs are "subject to Phase 2 and other future processes, for which timelines have not been set." The Phase 1 CBP refund process (live April 20 post-SCOTUS Feb 20 ruling) does not cover CAH categories. Q3 margin compressed to 0.79% vs 1.26% PY. FY2026 GMPD guide $150M; nine-month actual $108M; Q4 implied $42M. Q3 run rate is $25M.

Navista & ION reporting unit $184M pre-tax goodwill impairment within one year of the ION acquisition (December 2024, ≈$1.1B). Discount rate 10.5%, terminal growth 3%. Sensitivity: +50bps → additional $70M. Trigger language: "changes in risk profile of the business plans." Specialty Alliance Units liability also grew $422M over nine months to $1.265B (physician equity mark-to-market growing faster than anticipated).

Nuclear/Theranostics $478M Q3 (+18.6% YoY) — deceleration from the +30% rate cited Q2.

Pharma segment profit $784M (+18.4% YoY); 9-month $2,138M (+24% YoY). GLP-1 increasing as revenue driver but "did not meaningfully contribute to segment profit." Non-GAAP EPS $3.17 (+35% YoY); 9-month $8.35. $1.8B buyback authorization remaining; $250M ASR concluded April 20 at $209.55 VWAP.

The cross-ticker check inverts the Nuclear bear. LNTH 10-Q (filed May 7) reported PYLARIFY $240.9M Q1 2026 vs $257.7M PY — -6.5% YoY. LNTH total +1.2% only via the Neuraceq acquisition. LNTH explicitly cited "three Ga-68-based PSMA imaging agents, an F-18-based PSMA imaging agent" plus NCE exclusivity expiring 2026 plus CMS post-TPT-Status reimbursement compression ("payments based on MUC...lower than payments based on average selling price"). CAH +18.6% vs LNTH -6.5% = ≈25pp spread. The CAH deceleration from Q2 +30% is comp-effect, not share loss. CAH's vertical model (manufacturing + distribution + theranostics + 70-product pipeline + PluVicto distribution) is taking share while LNTH compresses.

What the market thinks

CAH trades at approximately 18x forward EPS (FY26E ≈$10.25). Peers: COR 18-19x, MCK 16-17x. CAH historically traded at premium due to specialty platform; current multiple is at-or-below cohort.

Options: ATM IV 34.2% (IV Rank 54%); ATM calls IV +6.0% above puts (unusual — typical skew is the inverse). P/C volume 0.20 (institutional call accumulation). Max pain $210, stock -14.3% below. Distress -25% implied 16% over 39d.

Sell-side consensus: 13 buys, average target ≈$215. The bull thesis cited is Pharma execution + specialty platform + Solaris MSO. The radiopharma cohort divergence is not in the narrative. Sell-side treats Nuclear as a small "Other" segment line at CAH and LNTH as the radiopharma growth pure-play.

LNTH rallied +14.3% over one month despite Pylarify weakness. Market is pricing LNTH on Neuraceq optionality and pipeline (Ga-68 edotreotide PDUFA June 29, MK-6240 tau PET August 13). The structural Pylarify decline is not yet priced.

The gap: market prices LNTH as the radiopharma winner; filings show CAH winning by ≈25pp.

Why the gap exists

Segment burial. CAH does not break out Nuclear profit separately — consolidated into "Other." The "Other" segment grew +34% YoY but at-Home Solutions (+38%, Apria/Advantia integration) drives most of the visible growth. Nuclear margin trajectory is invisible. Sell-side models cannot isolate the radiopharma economics.

Coverage asymmetry. CAH analysts focus on drug distribution, GMPD turnaround, Solaris/MSO. LNTH analysts focus on PYLARIFY, Ga-68 PDUFA, theranostics M&A. No analyst covers both. The cohort comparison requires reading two 10-Qs filed a week apart and synthesizing.

Comp-effect masquerading as deceleration. Headline "Nuclear decelerated from +30% to +18.6%" reads bearish in isolation. With LNTH Q1 -6.5% as cohort context, +18.6% reads as share gain.

Risks

Tariff durability (highest). CAH's Phase 2+ stuck position is durable until policy resolves. If GMPD Q4 prints near the $25M Q3 run rate again, FY2026 misses $150M guide and breaks the 4-consecutive-raise streak. The cohort cross-check confirmed CAH alone in this severity (HSIC IEEPA "not material," COR/MCK structurally insulated as drug distributors). Genuinely idio — won't compress sectorally.

MSO platform risk (medium). ION impairment within one year signals the oncology MSO did not perform to deal model. Solaris (urology, $1.9B closed Nov 2025) just started integration. If Solaris shows similar dynamics 12-18 months in, the rollup strategy is broken and the specialty platform thesis weakens materially. Specialty Alliance Units liability already +$422M in nine months.

Multi-PSMA competitive entry (latent). Telix Pixclara approved as F-18 PSMA agent. If competitors take share at CAH distribution sites too (not just at LNTH), the radiopharma divergence flips from share-gain to share-loss.

Litigation tail (low). IRS NOPA ≈$160M (FY2015-2020, Patient Recovery acquisition restructuring). WV opioid Fourth Circuit vacated favorable judgment Oct 2025, remanded. Combined ≈$200M+ before reserves. Incremental, not existential.

Catalysts

The August 5-15 window is the cluster. Two-leg validation: if both CAH Nuclear ≥+12% AND LNTH PYLARIFY ≤$250M, the divergence factor confirms the share-gain state. Split outcome diagnoses which leg drove divergence; both miss compresses the thesis.

What would change our mind

• LNTH PYLARIFY Q2 2026 prints above $260M (positive YoY). The pricing reset thesis (new formulation March 6 PDUFA + TPT) may have materialized. CAH-vs-LNTH share narrative breaks.
• Telix or another PSMA competitor takes share at CAH distribution sites — would show as CAH Nuclear Q4 below +8% YoY.
• CAH adds explicit Nuclear segment disclosure (margin, growth) in Q4 print or investor day. Better disclosure means sell-side can model the alpha and it gets priced.
• CMS proposed rule cuts theranostics reimbursement broadly. Sectoral compression hits both CAH and LNTH; divergence factor decays.
• CAH discloses second MSO impairment (Solaris-related). Specialty platform thesis breaks; Pharma is the only thing left.

Vehicle note

CAH idio variance is 29.5% — most CAH variance is healthcare-distribution beta, not stock-specific. Nuclear is <1% of revenue. The radiopharma alpha contribution to CAH stock is small (~+1.5% over 365d via factor-loading math). LNTH at 46.2% idio is conceptually cleaner for capturing this signal, but options pricing (49.6% IV, IV Rank elevated, +14% recent move, 10.4% short interest) makes the entry expensive and tape direction wrong. A paired position does not isolate the factor cleanly: LNTH β = -0.08 means it carries ~+0.62 net long market exposure. The pattern is real and durable; the vehicle is imperfect.

Evidence